Compare · AAPG vs NVO
AAPG vs NVO
Side-by-side comparison of Ascentage Pharma Group International (AAPG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AAPG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 148.2x AAPG ($1.16B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 7 for AAPG).
- NVO has more recent analyst coverage (25 ratings vs 11 for AAPG).
- Company
- Ascentage Pharma Group International
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.16B
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -20.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 9
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AAPG
- Amendment: SEC Form 6-K/A filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S